Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck

Presant, Cary A.; Ratkin, Gary; Klahr, Carol; Brown, C.M.

doi:10.1002/1097-0142(197911)44:5<1571::aid-cncr2820440505>3.0.co;2-r

Cited by 15 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…rouracil, Adriamycin, Vincristin, Vinbiastin, Endoxan, CCNU, Mitomycin, Zytoxan, Hydroxyurea (1,3,19,27,29,34,42,43 In addition, 15 mg. Bleomycin was administered weekly. Hydratation and diuresis were forced by 1000 ml.…”

mentioning

confidence: 99%

Konzept einer ambulanten Kombinationstherapie mit Cisplatin, Bleomycin (DDP-BLM) bei Rezidiven und Metastasen maligner Tumoren des Kopfes und Halses

Mika¹,

Wissen-Siegert²

1983

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

Einteitung Die Uberlebensraten für Patienten mit malignen Kopf-und Haistumoren der Stadien T3-T4 werden mit 10-30% angegeben (4, 14, 25, 34, 37, 38). Diese statistischen Daten geben keine Auskunft die Lebensqualität wahrend der Ietzten Lebensrnonate und Jahre, die häufig durch em Karzinornrezidiv bestimmt wird. Ausgedehnte chirurgische MaInahrnen mit Total-oder Teilentfernung von Larynx, Pharynxtrichter, Zunge, Unterkiefer oder Oberkiefer, mit radikaler Ausräumung der Halslymphknoten lassen beim Aultreten eines Karzinomrezidivs oder einer lokalen Metastase kaurn eine erneute chirurgische oder strahlentherapeutische Intervention zu. Urn so mehr bediirfen die betroffenen Patienten neben einer guten Pflege einer gezielten antikanzerösen und analgetischen Behandlung, wenn zur funktionellen und kosmetischen Entstellung nach langdauernder Behandlung das Lokalrezidiv mit weiteren einschneidenden Beschränkungen der Lebensqualität auftritt. Inwieweit als Ietzte mogliche Manahrne der Einsatz von Zytostatika gerechtfertigt ist, hangt weitgehend vorn Aus-rna1 und der Lokalisation des Rezidivs bzw. der Metastase und vom Allgemeinzustand des Patienten ab (21).

show abstract

mentioning

confidence: 99%

Konzept einer ambulanten Kombinationstherapie mit Cisplatin, Bleomycin (DDP-BLM) bei Rezidiven und Metastasen maligner Tumoren des Kopfes und Halses

Mika¹,

Wissen-Siegert²

1983

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

show abstract

Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide

Presant

Amburg

Klahr

et al. 1980

Cancer

Self Cite

View full text Add to dashboard Cite

A phase II trial of Adriamycin, BCNU, and cyclophosphamide was performed in 29 patients with advanced prostatic carcinoma (Southeastern Cancer Study Group protocol SEG 76 PR 0102P). Therapy consisted of BCNU 100 mg/m2, plus cyclophosphamide, 300 mg/m2 i.v., on day 1, followed by Adriamycin, 30 mg/m2 i.v., on day 2. Therapy was repeated every four weeks. In 27 evaluable patients refractory to prior estrogen therapy, one patient had a complete response, six patients had partial responses, and two patients had objective improvement (complete plus partial response rate 26%, and overall response rate 33%). Responders had a median time to progression of disease of 5.5 months, compared with a median time to progression of 4.0 months for those patients with stable disease. The median survival of responders was 9.3 months, compared with 6.7 months for stable disease and 3.9 months for patients with progression. Patients with higher pretreatment performance status did not have higher response rates. No life-threatening toxicity was observed. Only five patients had nadir platelet counts below 50,000/mm3, and only six patients had nadir granulocyte counts below 750/mm3. This regimen palliates the effects of hormone-resistant metastatic prostatic carcinoma.

show abstract

Failure of short-course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer

Tannock

Sutherland

Osoba

1982

Cancer

View full text Add to dashboard Cite

Fifty-seven patients with advanced cancer (52 with squamous cell carcinoma of the head and neck) were treated with short-course, multiple drug chemotherapy using schedules that were similar to those proposed by Price et al. Chemotherapy consisted of vincristine, methotrexate and folinic acid rescue, bleomycin, and FU, with or without Adriamycin and hydroxyurea. Most patients had received radiation therapy. There were only six objective responses (one CR, five PR) and except for one patient who is alive without disease following subsequent radiation the remissions were of short duration. Most patients tolerated treatment well but there was one toxic death, two sudden deaths of unknown cause, and renal impairment, mucositis, myelosuppression, or bleomycin skin toxicity in 14 others. Our results differ from those of Price et al. and do not support a role for this type of chemotherapy in the treatment of recurrent or metastatic head and neck cancer.

show abstract

Adriamycin, BCNU plus cyclophosphamide (ABC) in advanced carcinoma of the head and neck

Cited by 15 publications

References 5 publications

Konzept einer ambulanten Kombinationstherapie mit Cisplatin, Bleomycin (DDP-BLM) bei Rezidiven und Metastasen maligner Tumoren des Kopfes und Halses

Konzept einer ambulanten Kombinationstherapie mit Cisplatin, Bleomycin (DDP-BLM) bei Rezidiven und Metastasen maligner Tumoren des Kopfes und Halses

Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide

Failure of short-course multiple drug chemotherapy to benefit patients with recurrent or metastatic head and neck cancer

Contact Info

Product

Resources

About